Shire is hosting an R&D Day for the investment community focused on the company’s pipeline of innovative medicines being developed to treat rare diseases and other specialty conditions. Shire has also announced a collaboration with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to support the Company’s Messenger RNA Technology platform for cystic fibrosis (CF), and Fast Track designation from the FDA for SHP607, a protein replacement therapy being developed for the prevention of Retinopathy of Prematurity (ROP).
“Shire’s clear and focused strategy has enabled us to transform our pipeline with 22 programmes in the clinic, the most in Shire’s history,” said Flemming Ornskov, MD, MPH, CEO.
“Our clinical and scientific capabilities in discovering new therapies for rare diseases are focused on new indications and therapeutic areas,” said Philip J. Vickers, PhD, Global Head of R&D. “We have a number of significant clinical milestones anticipated over the next 18 months, and aim to accelerate delivery of therapies to patients from a highly productive internal pipeline, complemented by the acquisition of external assets and innovative collaborations.”
